Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8712
Reference
MSAN(2026)18
Name
Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches – Update
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
Scotland
Health Boards
Supplies
Pharmaceutical Services
Description
Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches are in limited supply until late September 2026.
Rivastigmine 13.3mg/ 24hours transdermal patch remains available but cannot support an uplift in demand.
Rivastigmine (Zeyzelf) twice weekly 4.6 mg/24hours transdermal patch remains available but cannot support an uplift in demand.
Rivastigmine (Zeyzelf) twice weekly 9.5 mg/24hours transdermal patch remains available but cannot support uplift in demand.
Unlicensed supplies of rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches are available.
Wholesalers will be monitoring sales carefully and may impose maximum sales volumes to support uninterrupted access for patients in primary care.
Alternative formulations of acetylcholinesterase (AChE) inhibitors remain available, except for galantamine modified release capsules which are also in limited supply (see Additional information section).
This MSAN supersedes MSAN(2025)51 issued on 9 December 2025.
Contact Name
Contact Email
Contact Address
Created
2026-06-16 07:47:29
Click to go back to homepage